Overview

Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to investigate if treatment of CMV infection by antiviral drug Valcyte (R) affects the clinical outcome of glioblastoma multiforme in patients with local CMV infection in tumor tissue. The investigators' hypothesis states that CMV infection promotes tumor development and disease progression and inhibits immune responses against the tumor.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Karolinska Institutet
Karolinska University Hospital
Collaborator:
Karolinska University Hospital
Treatments:
Ganciclovir
Valganciclovir
Criteria
Inclusion Criteria:

- Glioblastoma grade IV

- Cytomegalovirus detected in tumor

- At least 90% resection of tumor

Exclusion Criteria:

- Decreased kidney function

- Pregnancy

- Neutropenia

- Thrombocytopenia

- Patient not tolerating the drug